Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Amgen, Inc. and AstraZeneca PLC’s tezepelumab showed significant efficacy in reducing patients’ annualized asthma exacerbation rate regardless of their eosinophil levels in the first detailed set of Phase III data in the treatment of severe uncontrolled asthma. The commercial potential remains unclear, however, since doctors say they are unlikely to switch patients with high eosinophil levels who are served well by existing biologics approved for that population.

Amgen and AstraZeneca previously reported positive top-line results from the NAVIGATOR trial and presented detailed primary endpoint results as part of the American Academy of Asthma Allergy and Immunology (AAAAI) virtual annual meeting on 26 February